Advertisement

FDA to require sunlamp products to carry label that minors are banned from use

The American Academy of Dermatology said people exposed to UV radiation via indoor tanning have a 59 percent increase in the risk of melanoma, the deadliest type of skin cancer.

By Alex Cukan
FDA to require warnings on sunlamp products. (UPI Photo/Roger L. Wollenberg)
FDA to require warnings on sunlamp products. (UPI Photo/Roger L. Wollenberg) | License Photo

WASHINGTON, May 29 (UPI) -- The U.S. Food and Drug Administration reclassified sunlamp products and ultraviolet lamps from low-risk to moderate-risk and now requires a warning that sunlamps should not used by those age 18 and younger.

The FDA order requires sunlamp products -- which include tanning beds and tanning booths -- carry a visible black-box warning on the device that states the product should not be used by anyone age 18 and younger.

Advertisement

In addition, certain marketing materials for sunlamp products and UV lamps must include additional and specific warning statements including: "Persons repeatedly exposed to UV radiation should be regularly evaluated for skin cancer."

Sunlamp products emit UV radiation that may cause skin cancer. The American Academy of Dermatology said people exposed to UV radiation via indoor tanning have a 59 percent increase in the risk of melanoma, the deadliest type of skin cancer.

"The FDA has taken an important step today to address the risk to public health from sunlamp products," Dr. Jeffrey Shuren, director of the FDA's Center for Devices and Radiological Health, said in a statement.

"Repeated UV exposure from sunlamp products poses a risk of skin cancer for all users -- but the highest risk for skin cancer is in young persons under the age of 18 and people with a family history of skin cancer."

Advertisement

Manufacturers will have to submit a premarket notification -- a "510(k)" -- to the FDA and obtain FDA clearance prior to marketing their devices. Before this order, the sunlamp manufacturers were exempt from premarket review.

Latest Headlines